vs
i-80 Gold Corp.（IAUX）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是i-80 Gold Corp.的1.4倍（$30.3M vs $21.3M），REGENXBIO Inc.净利率更高（-221.3% vs -401.9%，领先180.5%），i-80 Gold Corp.自由现金流更多（$-39.2M vs $-52.8M）
i-80黄金公司是一家主营贵金属勘探开发的矿业企业，核心业务布局位于美国内华达州，主打黄金、银矿项目的勘测、开发与合规开采，所产出的贵金属资源主要供应全球工业及投资市场。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
IAUX vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.4倍
$21.3M
净利率更高
RGNX
高出180.5%
-401.9%
自由现金流更多
IAUX
多$13.6M
$-52.8M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $21.3M | $30.3M |
| 净利润 | $-85.6M | $-67.1M |
| 毛利率 | 22.0% | — |
| 营业利润率 | -291.6% | -190.0% |
| 净利率 | -401.9% | -221.3% |
| 营收同比 | — | 43.0% |
| 净利润同比 | — | -31.2% |
| 每股收益（稀释后） | $-0.10 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IAUXRGNX
| Q4 25 | $21.3M | $30.3M | ||
| Q3 25 | $32.0M | $29.7M | ||
| Q2 25 | $27.8M | $21.4M | ||
| Q1 25 | $14.0M | $89.0M | ||
| Q4 24 | — | $21.2M | ||
| Q3 24 | $11.5M | $24.2M | ||
| Q2 24 | $7.2M | $22.3M | ||
| Q1 24 | — | $15.6M |
净利润IAUXRGNX
| Q4 25 | $-85.6M | $-67.1M | ||
| Q3 25 | $-41.9M | $-61.9M | ||
| Q2 25 | $-30.2M | $-70.9M | ||
| Q1 25 | $-41.2M | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $-43.1M | $-59.6M | ||
| Q2 24 | $-41.0M | $-53.0M | ||
| Q1 24 | — | $-63.3M |
毛利率IAUXRGNX
| Q4 25 | 22.0% | — | ||
| Q3 25 | 9.7% | — | ||
| Q2 25 | 2.9% | — | ||
| Q1 25 | 20.7% | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | -42.7% | 48.8% | ||
| Q2 24 | -171.4% | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率IAUXRGNX
| Q4 25 | -291.6% | -190.0% | ||
| Q3 25 | -86.7% | -176.3% | ||
| Q2 25 | -67.4% | -296.3% | ||
| Q1 25 | -112.3% | 13.6% | ||
| Q4 24 | — | -242.1% | ||
| Q3 24 | -210.0% | -256.6% | ||
| Q2 24 | -435.2% | -251.3% | ||
| Q1 24 | — | -408.8% |
净利率IAUXRGNX
| Q4 25 | -401.9% | -221.3% | ||
| Q3 25 | -130.8% | -208.3% | ||
| Q2 25 | -108.5% | -331.8% | ||
| Q1 25 | -293.3% | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | -374.5% | -246.3% | ||
| Q2 24 | -570.8% | -237.7% | ||
| Q1 24 | — | -405.4% |
每股收益（稀释后）IAUXRGNX
| Q4 25 | $-0.10 | $-1.30 | ||
| Q3 25 | $-0.05 | $-1.20 | ||
| Q2 25 | $-0.05 | $-1.38 | ||
| Q1 25 | $-0.10 | $0.12 | ||
| Q4 24 | — | $-0.99 | ||
| Q3 24 | $-0.11 | $-1.17 | ||
| Q2 24 | $-0.11 | $-1.05 | ||
| Q1 24 | — | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.2M | $230.1M |
| 总债务越低越好 | $174.7M | — |
| 股东权益账面价值 | $346.8M | $102.7M |
| 总资产 | $703.4M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.50× | — |
8季度趋势，按日历期对齐
现金及短期投资IAUXRGNX
| Q4 25 | $63.2M | $230.1M | ||
| Q3 25 | $102.9M | $274.2M | ||
| Q2 25 | $133.7M | $323.3M | ||
| Q1 25 | $13.5M | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | $21.8M | $255.5M | ||
| Q2 24 | $47.8M | $290.4M | ||
| Q1 24 | — | $338.7M |
总债务IAUXRGNX
| Q4 25 | $174.7M | — | ||
| Q3 25 | $175.9M | — | ||
| Q2 25 | $175.8M | — | ||
| Q1 25 | $197.5M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益IAUXRGNX
| Q4 25 | $346.8M | $102.7M | ||
| Q3 25 | $423.0M | $161.5M | ||
| Q2 25 | $463.5M | $213.7M | ||
| Q1 25 | $318.0M | $274.2M | ||
| Q4 24 | — | $259.7M | ||
| Q3 24 | $346.9M | $301.4M | ||
| Q2 24 | $377.2M | $348.3M | ||
| Q1 24 | — | $390.7M |
总资产IAUXRGNX
| Q4 25 | $703.4M | $453.0M | ||
| Q3 25 | $756.2M | $525.2M | ||
| Q2 25 | $782.9M | $581.0M | ||
| Q1 25 | $659.0M | $490.9M | ||
| Q4 24 | — | $466.0M | ||
| Q3 24 | — | $519.1M | ||
| Q2 24 | — | $569.4M | ||
| Q1 24 | — | $629.2M |
负债/权益比IAUXRGNX
| Q4 25 | 0.50× | — | ||
| Q3 25 | 0.42× | — | ||
| Q2 25 | 0.38× | — | ||
| Q1 25 | 0.62× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-34.3M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-39.2M | $-52.8M |
| 自由现金流率自由现金流/营收 | -184.3% | -174.0% |
| 资本支出强度资本支出/营收 | 23.1% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-93.2M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流IAUXRGNX
| Q4 25 | $-34.3M | $-52.3M | ||
| Q3 25 | $-15.2M | $-56.0M | ||
| Q2 25 | $-11.3M | $-49.3M | ||
| Q1 25 | $-22.7M | $33.6M | ||
| Q4 24 | — | $-31.6M | ||
| Q3 24 | $-23.5M | $-40.5M | ||
| Q2 24 | $-24.6M | $-45.5M | ||
| Q1 24 | — | $-55.5M |
自由现金流IAUXRGNX
| Q4 25 | $-39.2M | $-52.8M | ||
| Q3 25 | $-18.5M | $-56.5M | ||
| Q2 25 | $-12.4M | $-49.7M | ||
| Q1 25 | $-23.1M | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | $-23.8M | $-40.9M | ||
| Q2 24 | $-25.1M | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率IAUXRGNX
| Q4 25 | -184.3% | -174.0% | ||
| Q3 25 | -57.8% | -189.9% | ||
| Q2 25 | -44.7% | -232.8% | ||
| Q1 25 | -164.1% | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | -206.7% | -168.9% | ||
| Q2 24 | -349.1% | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度IAUXRGNX
| Q4 25 | 23.1% | 1.7% | ||
| Q3 25 | 10.2% | 1.7% | ||
| Q2 25 | 3.9% | 1.8% | ||
| Q1 25 | 2.5% | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | 2.5% | 1.3% | ||
| Q2 24 | 7.3% | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率IAUXRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IAUX
| Granite Creek Mining Company | $20.3M | 95% |
| Ruby Hill Mining Company LLC | $991.0K | 5% |
| Lone Tree Minning Company | $3.0K | 0% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
